Comparison of costs associated with the use of etanercept, infliximab, and adalimumab for the treatment of rheumatoid arthritis.

Bullano, Michael F; McNeeley, Brian J; Yu, Yanni F; Quimbo, Ralph; Burawski, Lauren P; Yu, Elaine B; Woolley, J Michael

Bullano, Michael F; McNeeley, Brian J; Yu, Yanni F; Quimbo, Ralph; Burawski, Lauren P; Yu, Elaine B; Woolley, J Michael.

Affiliation

Bullano MF; Health Outcomes Research, HealthCore, Inc., Wilmington, Delaware 19801, USA.

Manag Care Interface ; 19(9): 47-53, 2006 Sep.

Article in En | MEDLINE | ID: mdl-17017313

Subject(s)

Anti-Inflammatory Agents, Non-Steroidal/economics; Antibodies, Monoclonal/economics; Arthritis, Rheumatoid/drug therapy; Immunoglobulin G/economics; Adalimumab; Anti-Inflammatory Agents, Non-Steroidal/administration & dosage; Anti-Inflammatory Agents, Non-Steroidal/therapeutic use; Antibodies, Monoclonal/administration & dosage; Antibodies, Monoclonal/therapeutic use; Antibodies, Monoclonal, Humanized; Etanercept; Humans; Immunoglobulin G/administration & dosage; Immunoglobulin G/therapeutic use; Infliximab; Receptors, Tumor Necrosis Factor/administration & dosage; Receptors, Tumor Necrosis Factor/therapeutic use; Retrospective Studies

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Arthritis, Rheumatoid / Immunoglobulin G / Anti-Inflammatory Agents, Non-Steroidal / Antibodies, Monoclonal Type of study: Health_economic_evaluation / Observational_studies / Risk_factors_studies Limits: Humans Language: En Journal: Manag Care Interface Journal subject: SERVICOS DE SAUDE Year: 2006 Type: Article Affiliation country: United States

Search on Google

XML

PubMed Links